NEW YORK – Myriad Genetics' stock finished Friday down about 18 percent following an announcement by UnitedHealthcare that it will no longer pay for pharmacogenetic multigene panel tests beginning Jan. 1, 2025.

纽约——联合医疗（UnitedHealthcare）宣布，自2025年1月1日起，Myriad Genetics的股票将不再支付药物遗传学多基因面板测试费用，周五收盘下跌约18%。

In a note to investors, JP Morgan analyst Rachel Vatnsdal wrote that the payor was the largest and first payor to reimburse for Myriad's GeneSight test, beginning in 2019. According to Vatnsdal, GeneSight represented approximately 18 percent of the company's total revenues in 2023.

摩根大通（JPMorgan）分析师雷切尔·瓦坦斯达尔（RachelVatnsdal）在给投资者的一份报告中写道，该付款人是自2019年开始偿还Myriad基因视力测试费用的最大付款人，也是第一个付款人。据Vatnsdal称，2023年，GeneSight约占公司总收入的18%。

In its new medical policy document, United now says that 'the use of pharmacogenetic multigene panels (five or more genes) for the evaluation of drug-metabolizer status is unproven and not medically necessary for any indication due to insufficient evidence of efficacy.'

United now在其新的医疗政策文件中表示，“使用药物遗传学多基因面板（五个或更多基因）评估药物代谢状态尚未得到证实，并且由于疗效证据不足，在医学上不需要任何适应症。”

The payor specifically cited a lack of evidence for the utility of PGx tests to guide the treatment of psychiatric and behavioral health conditions and cardiovascular disease, and it called the evidence for PGx multigene testing in general 'insufficient at this time.'

付款人特别指出，缺乏证据表明PGx检测可用于指导精神和行为健康状况以及心血管疾病的治疗，并称目前PGx多基因检测的证据总体上“不足”

In the context of anthracycline chemotherapy drugs, United said that although early evidence is promising, additional prospective studies with long-term follow-up are needed to validate PGx testing in this setting.

在蒽环类化疗药物的背景下，United表示，尽管早期证据很有希望，但还需要进行长期随访的其他前瞻性研究，以验证这种情况下的PGx检测。

'We believe this announcement was unexpected and will likely weigh on the [long-term] trajectory of Myriad's GeneSight portfolio,' especially with the company having previously projected double-digit volume growth in this market, Vatnsdal wrote. She called United's move 'further proof' that Myriad faces significant hurdles in achieving widespread reimbursement for GeneSight..

。她称曼联的举动“进一步证明”，Myriad在实现GeneSight的广泛报销方面面临重大障碍。。

Shares of Myriad were trading at $17.99 on the Nasdaq at the close of market on Friday.

周五收盘时，Myriad的股价在纳斯达克收于17.99美元。